{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Schedules of Activities",
        "description": "Reference to affected schedules regarding C-SSRS administration"
      },
      {
        "id": "ref_2",
        "name": "Section 6 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6",
        "sectionTitle": "Study Procedures",
        "description": "Reference to Section 6 regarding C-SSRS administration and dosing"
      },
      {
        "id": "ref_3",
        "name": "Section 5 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5",
        "sectionTitle": "Study Treatments",
        "description": "Reference to Section 5 regarding dosing administration and rescue treatment"
      },
      {
        "id": "ref_4",
        "name": "Section 1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1",
        "sectionTitle": "Introduction",
        "description": "Reference to Section 1 for PK metabolite analysis and background"
      },
      {
        "id": "ref_5",
        "name": "Section 2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Study Objectives and Endpoints",
        "description": "Reference to Section 2 for PK analysis and objectives"
      },
      {
        "id": "ref_6",
        "name": "Section 7 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Assessments",
        "description": "Reference to Section 7 for PK analysis and patient reported outcomes"
      },
      {
        "id": "ref_7",
        "name": "Appendix 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Prohibited Concomitant Medications",
        "description": "Reference to washout periods for CYP2C9 and CYP2C19 inducers"
      },
      {
        "id": "ref_8",
        "name": "Section 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4",
        "sectionTitle": "Study Population",
        "description": "Reference to Section 4 regarding Hepatitis B monitoring and study design"
      },
      {
        "id": "ref_9",
        "name": "Section 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3",
        "sectionTitle": "Study Design",
        "description": "Reference to Section 3 regarding study design and dosing interruptions"
      },
      {
        "id": "ref_10",
        "name": "Section 9 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Statistical Methods and Data Analysis",
        "description": "Reference to Section 9 for per-protocol analysis and endpoint definitions"
      },
      {
        "id": "ref_11",
        "name": "Appendix 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Discontinuation Criteria",
        "description": "Reference to temporary interruption of dosing and discontinuation criteria"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The C-SSRS will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including the EOT/ET and/or the EOS visit.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 5",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "For Taiwan only: Similar to China, other countries in Asia... will adopt the same changes as those proposed for China in Amendment 3 to monitor the risk of hepatitis B reactivation.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 4",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "These changes are in effect for China only: Subjects who are HBsAg negative, HBcAb positive, and HBsAb positive at Screening will have reflex testing for HBV DNA.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 3",
        "pageNumber": 3
      },
      {
        "id": "annot_4",
        "text": "Defined medicated topical therapy as a topical product that contains an active pharmaceutical ingredient indicated for the treatment of AD (irrespective of whether it is an OTC or prescribed product).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 2",
        "pageNumber": 4
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-10-28",
        "description": "Incorporation of C-SSRS administration, endpoint rewording, and administrative clarifications.",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_2",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-11-27",
        "description": "Hepatitis B monitoring changes for Taiwan.",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-09-12",
        "description": "Hepatitis B reflex testing and discontinuation criteria for China.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_4",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-07-23",
        "description": "Updates to background, objectives, study design, and GDPR language.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_5",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-06-20",
        "description": "Initial revisions.",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 11,
      "annotationCount": 4,
      "versionCount": 5
    }
  }
}